TRT Delivery 2026 Gels, Autoinjectors, and Oral Options

Compare gels, weekly subcutaneous autoinjectors, and oral testosterone undecanoate on dosing cadence, lifestyle fit, and safety in 2026. Use this guide to plan a discussion with your clinician.

Estimated reading time: 9 minutes

Key takeaways

• No universal “best” TRT route: gels, weekly subcutaneous autoinjectors, and oral testosterone undecanoate all restore average testosterone to target ranges in Phase 3 studies but differ in cadence, day-to-day fit, and safety nuances.
• FDA 2025 updates: the boxed cardiovascular warning was removed after TRAVERSE showed no increase in MACE for gel vs placebo; labels now emphasize class-wide blood pressure increases and restrict TRT to confirmed hypogonadism.
• Practicality drives adherence: gels require daily application and transfer precautions; autoinjectors provide a once-weekly routine; oral undecanoate is needle-free but typically twice daily.
• Monitoring is essential across all routes: hematocrit and blood pressure can rise; ongoing labs and follow-up are part of safe use.

Testosterone replacement therapy (TRT) continues to evolve, but the most commonly used delivery methods in 2026 remain familiar: daily transdermal gels, weekly subcutaneous autoinjectors, and twice-daily oral testosterone undecanoate. Each restores testosterone into typical eugonadal ranges for hypogonadal men in Phase 3 studies. The trade-offs live in how these options deliver hormone (pharmacokinetics), how people actually use them (adherence), and what patients say they prefer in everyday life (needle-free vs convenience vs routine). There isn’t a single best TRT delivery method for everyone—choosing well depends on goals, risks, and lifestyle fit.

What’s New Since 2025: Safety Labeling and Class-Wide Updates

In early 2025, the FDA updated labeling for all prescription testosterone products with two major changes:

• Cardiovascular risk update: Based on TRAVERSE (a large outcomes study using a transdermal gel), TRT did not increase major adverse cardiovascular events versus placebo (hazard ratio 0.96; 95% CI 0.78–1.17). The FDA removed the boxed CV warning, though uncertainty remains and broader long-term outcomes are still being studied.
• Blood pressure warnings: Labeling now highlights class-wide increases in blood pressure observed in ABPM (ambulatory blood pressure monitoring) studies across formulations (including oral and subcutaneous). Monitoring is emphasized.

At the same time, labeling continues to restrict TRT to men with confirmed hypogonadism, not age-related low testosterone alone. The requirement to confirm low morning testosterone on two separate days remains standard.

The Big Three Delivery Methods in 2026

This overview focuses on the formulations most commonly compared by patients and clinicians today: transdermal gels, subcutaneous autoinjectors like Xyosted, and oral testosterone undecanoate such as Tlando.

Transdermal Gels (e.g., AndroGel 1.62%)

• Pharmacokinetics: Designed to deliver a steady daily release that approximates physiologic patterns. Absorbed through the skin, with dose adjustments based on blood levels.
• Efficacy: Phase 3 programs show restoration of average testosterone (Cavg) into the eugonadal range in most treated men.
• Practical pros: Needle-free; once-daily routine; widely covered by insurers; easy to titrate.
• Practical cons: Requires daily adherence and clean application technique; potential for skin irritation; transfer risk to partners or children if not fully dry or covered; bathing/sweat timing considerations.
• Who may prefer it: Men who want a needle-free option with steady day-to-day levels, who can commit to a daily routine and follow application precautions.

Subcutaneous Autoinjectors (e.g., Xyosted)

• Pharmacokinetics: Weekly subcutaneous dosing (commonly in the 50–100 mg range in studies) produces relatively stable serum testosterone between doses. Phase 3 data report about 90% of men maintaining average testosterone in the target range.
• Efficacy: Multiple Phase 3 trials showed on-target Cavg in most men, with consistent week-to-week profiles.
• Practical pros: Weekly at-home dosing; fewer clinic visits compared with some intramuscular options; device is designed to simplify injections and reduce needle handling stress.
• Practical cons: Still involves needles; injection-site reactions possible; requires training on device use; dose titration may require periodic labs. Product labels highlight regular hematocrit monitoring (e.g., every 3 months early on).
• Who may prefer it: Men who want to avoid daily application and are comfortable with a once-weekly, structured routine using an autoinjector.

Oral Testosterone Undecanoate (e.g., Tlando)

• Pharmacokinetics: Taken twice daily. Phase 3 programs met the primary endpoint of restoring average testosterone to target ranges, though early analyses noted a lower-than-desired percentage meeting a stricter peak (Cmax) threshold (e.g., 74% vs an 85% target), which was later addressed in regulatory review.
• Efficacy: Achieved the main eugonadal Cavg endpoint in pivotal trials.
• Practical pros: Fully needle-free; no skin transfer risk; familiar twice-daily pill routine for many patients.
• Practical cons: Requires rigid adherence (BID dosing); absorption and level variability are active areas of discussion; routine labs for dose adequacy and safety still required.
• Who may prefer it: Men who strongly prefer to avoid injections and gels and can reliably take a medication twice daily.

How They Compare: Pharmacokinetics, Adherence, and Preferences

• Pharmacokinetics
  • Gels: Daily application leads to relatively smooth exposure and the ability to titrate in small steps.
  • Autoinjectors: Weekly subcutaneous delivery aims for consistent levels throughout the week for most patients.
  • Oral undecanoate: Twice-daily dosing is effective for average exposure; some variability in peak levels is noted in trial documents.
• Adherence
  • Daily vs weekly matters. Gels and oral formulations rely on day-to-day habits, while weekly autoinjectors concentrate adherence into a single scheduled moment.
  • No large head-to-head Phase 3 trials definitively show better adherence with one method over another. Real-world adherence is often about lifestyle fit.
• Patient preferences
  • Needle-free appeal is real: some patients prefer gels or oral capsules to avoid injections entirely.
  • Convenience can trump needle aversion for others: a once-weekly autoinjector may be easier to remember and eliminates gel transfer concerns.
  • Clinic burden: Autoinjectors decrease the need for in-office injections compared with traditional intramuscular regimens.

In practice, the “best TRT delivery method” tends to be the one a patient can and will use consistently, that achieves target levels without undue side effects, and that aligns with personal preferences around needles, skin application, or twice-daily routines.

What Phase 3 Data Tell Us—and Don’t

• Gels: Established Phase 3 data show reliable restoration to eugonadal ranges with careful titration.
• Subcutaneous autoinjectors (Xyosted): Across Phase 3 trials enrolling over 250 participants, approximately 90% reached target average testosterone with consistent weekly profiles.
• Oral testosterone undecanoate (Tlando): Met primary efficacy endpoints for average testosterone; initial concerns about peak thresholds (Cmax) were examined during review.

Important caveats:

• Many TRT trials are short-term (approximately 6–52 weeks), open-label, and not head-to-head against other modalities. This limits direct comparisons of long-term outcomes, adherence, and patient-reported preferences.
• Populations often skew younger than 65 and may not reflect all comorbidities seen in routine practice.
• Earlier meta-analyses on cardiovascular outcomes showed heterogeneity and potential bias; TRAVERSE provides reassuring MACE data for gels, but longer-term, modality-specific CV and prostate outcomes remain under study.

Safety, Monitoring, and Uncertainties

Class-wide considerations apply across gels, autoinjectors, and orals:

• Blood pressure: Labeling warns of increases in blood pressure across formulations, based on ABPM studies. Monitoring is part of routine care.
• Hematocrit/erythrocytosis: TRT can increase red blood cell mass. Product labels emphasize periodic hematocrit checks (with some specifying frequent early monitoring).
• Cardiovascular risk: TRAVERSE reported no increased risk of major adverse cardiovascular events for gels versus placebo. However, the field is still gathering longer-term, formulation-specific data.
• Prostate health: Ongoing monitoring remains standard; long-term outcomes require further study.
• Fertility: Exogenous testosterone can suppress gonadotropins and reduce sperm production. Men wishing to preserve fertility should discuss alternatives before starting TRT.
• Indication limits: TRT is for confirmed hypogonadism, not for age-related declines in testosterone absent diagnostic criteria.

Given that safety signals like blood pressure and hematocrit changes can occur across all delivery routes, the choice of route does not eliminate the need for careful follow-up.

Practical Fit: Matching Method to Lifestyle

Consider these everyday factors when comparing gel vs injection vs oral testosterone undecanoate:

• Daily routine tolerance:
  • If daily steps are easy, gels or oral BID may fit well.
  • If a weekly anchor is easier, autoinjectors are compelling.
• Needle comfort:
  • For needle-averse patients, gels or orals remove the injection barrier.
  • For those open to self-injection, autoinjectors minimize hands-on needle handling.
• Skin and transfer concerns:
  • Gels require careful application and drying to reduce transfer risk.
  • Autoinjectors and orals avoid skin transfer issues.
• Lab titration and monitoring:
  • All routes need lab follow-up; some products specify tighter early monitoring (e.g., hematocrit with autoinjectors).
  • Discuss with your clinician how often levels will be checked and how dose adjustments work for each route.
• Insurance and access:
  • Coverage can differ among formulations and brands. Many patients find gels well-covered; autoinjectors and oral options vary. A care team can help navigate benefits and prior authorizations.

Who Might Prefer Each Route?

Transdermal gels:

• Prefer a steady, daily routine
• Want fine-tuned dose adjustments
• Comfortable with skin application and transfer precautions

Subcutaneous autoinjectors:

• Prefer once-weekly dosing
• Want to avoid clinic-based injections
• Comfortable with a pen-like device and periodic labs

Oral testosterone undecanoate:

• Prioritize completely needle-free treatment
• Comfortable with twice-daily dosing
• Prefer to avoid topical precautions

Open Questions for 2026 and Beyond

• Head-to-head trials: We still need robust direct comparisons among gels, subcutaneous autoinjectors, and oral undecanoate for adherence, patient-reported outcomes, and pharmacokinetic consistency over time.
• Longer-term outcomes: Now that TRAVERSE reduces uncertainty about MACE with gel therapy, it remains to be seen whether similar long-term data will clarify cardiovascular and prostate outcomes across other formulations.
• Fertility-preserving pathways: For men prioritizing fertility, TRT’s suppressive effects on spermatogenesis remain a core challenge. Alternative strategies are under study.
• Innovation pace: As of 2026, no major new delivery breakthroughs have replaced the big three options in routine use, though incremental device and labeling changes continue.

How Taurus Meds Can Help

Selecting a TRT route is a shared decision that balances evidence, risk, and daily life. Our clinical team helps men:

• Confirm diagnostic criteria for hypogonadism
• Review formulation pros and cons in the context of your health history and preferences
• Navigate insurance coverage and access
• Coordinate monitoring plans that align with current labeling and safety guidance

We emphasize clear expectations, practical fit, and ongoing evaluation so that your therapy remains appropriate over time.

Conclusion

The question isn’t “what is the best TRT delivery method,” but “what is the best method for you.” Gels, weekly subcutaneous autoinjectors, and oral testosterone undecanoate all restore average testosterone levels into goal ranges for most men with confirmed hypogonadism in Phase 3 studies. The real-world differences show up in dose cadence (daily vs weekly vs twice daily), lifestyle compatibility, and user preferences—alongside shared safety considerations like blood pressure and hematocrit monitoring. With the FDA’s 2025 labeling updates and reassuring TRAVERSE findings for gels, the field is better equipped to focus on individualized selection and long-term follow-up. Work with a clinician to align the route with your goals, risks, and day-to-day life.

Disclaimer

This article is for educational purposes only and is not medical advice. Do not start, change, or stop any medication without consulting a qualified healthcare professional.

Sources

• FDA testosterone guidance (PDF)
• PubMed: Subcutaneous testosterone autoinjector study
• FDA: Testosterone information (postmarket safety)
• FDA issues class-wide labeling changes to testosterone products
• FDA NDA 209863 Summary Review (PDF)
• FDA NDA 208088 Summary Review (PDF)